CAMBRIDGE, England, June 6, 2013 /PRNewswire/ --
Sphere Fluidics Limited has developed unique technology for single cell analysis and characterization and provides proprietary products and novel services for this rapidly-growing market. This enabling approach can find rare variants in large cell populations and Sphere Fluidics has patented novel Cyto-Mine™ technology that permits up to one billion assays per biochip per day. Their technology provides significant operational benefits for biopharmaceutical discovery and development, cancer variation studies, analysis of antibiotic-resistance mutants and identification of novel enzymes and synthetic biology pathways. Sphere Fluidics has just recently completed a funding round of €2 million.
The firm has used the funding to recruit more scientists and has now hired a new Commercial Director (Dr Rob Marchmont, who previously held Senior Commercial positions with NanoInk and GE Healthcare and has more than 25 years in the Life Sciences market) to help grow the business. "I am thrilled to be joining the Sphere Fluidics team and look forward to building their business based on the success already gained, and developing new markets for single cell analysis." says Dr. Marchmont. "This week we are also launching a range of novel Pico-Gen™ biochips and specialist chemicals which can be used to make small pl-nl volume droplets (picodroplets) in which hundreds of millions of different single cell or molecule tests can be done" says Dr. Marchmont. "The Company has also developed research instrumentation in this area and has started comprehensive market analysis to ensure maximum impact of our "next generation" systems".
Sphere Fluidics now has over 70 different, international organizations buying their products. These include leading pharmaceutical companies (e.g. Roche, Novartis), Life Sciences biotechs (e.g. Illumina, Oxford Nanopore) and well-known research institutions (e.g. Harvard University, Imperial College, Max Planck Institut). The Company has also worked on collaborative research projects with a number of international companies.
Sphere Fluidics has also announced this week that it is relocating to brand new labs and office space at Babraham Research Campus. This is part of their expansion plans to enable international growth. Dr. Craig, Sphere Fluidics' CEO, says "Current activities show that we are accelerating our growth. Sphere Fluidics has also generated increased revenues from last year and we now plan to advance our "Discovery Services" business. We have an exciting year ahead!"
Sphere Fluidics Limited. Contact Dr Frank F. Craig on:
SOURCE Sphere Fluidics Limited